Skip to main content

Condylomata Acuminata

10
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
5
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
8100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Medigene
MedigeneGermany - Planegg-Martinsried
1 program
1
Polyphenon E Ointment 10%, Polyphenon E Ointment 15%Phase 31 trial
Active Trials
NCT00449982Completed480Est. Aug 2004
Innovax
InnovaxChina - Haicang District
4 programs
2
2
HPV Vaccine,270μg/1.0mlPhase 2Vaccine
low dosage HPV VaccinePhase 2Vaccine
HPV Vaccine,135μg/0.5mlPhase 1Vaccine
low dosage HPV VaccinePhase 1Vaccine
Enterprise Therapeutics
4 programs
2
2
HPV Vaccine,270μg/1.0mlPhase 2Vaccine1 trial
low dosage HPV VaccinePhase 2Vaccine1 trial
HPV Vaccine,135μg/0.5mlPhase 1Vaccine1 trial
low dosage HPV VaccinePhase 1Vaccine1 trial
Active Trials
NCT03813940Completed24Est. Apr 2021
NCT02405520Completed145Est. May 2022
NCT03935204Completed627Est. Apr 2021
+1 more trials
Verrica Pharmaceuticals
Verrica PharmaceuticalsPA - West Chester
1 program
1
VP-102 and applicatorPhase 21 trial
Active Trials
NCT03981822Completed105Est. Jul 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MedigenePolyphenon E Ointment 10%, Polyphenon E Ointment 15%
Verrica PharmaceuticalsVP-102 and applicator
Enterprise TherapeuticsHPV Vaccine,270μg/1.0ml
Enterprise Therapeuticslow dosage HPV Vaccine
Enterprise TherapeuticsHPV Vaccine,135μg/0.5ml
Enterprise Therapeuticslow dosage HPV Vaccine

Clinical Trials (6)

Total enrollment: 2,021 patients across 6 trials

NCT00449982MedigenePolyphenon E Ointment 10%, Polyphenon E Ointment 15%

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

Start: Jul 2003Est. completion: Aug 2004480 patients
Phase 3Completed
NCT03981822Verrica PharmaceuticalsVP-102 and applicator

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Start: Jun 2019Est. completion: Jul 2020105 patients
Phase 2Completed
NCT03935204Enterprise TherapeuticsHPV Vaccine,270μg/1.0ml

Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Start: May 2019Est. completion: Apr 2021627 patients
Phase 2Completed
NCT02710851Enterprise Therapeuticslow dosage HPV Vaccine

Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Start: Mar 2016Est. completion: Dec 2023640 patients
Phase 2Unknown
NCT03813940Enterprise TherapeuticsHPV Vaccine,135μg/0.5ml

Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Start: Jan 2019Est. completion: Apr 202124 patients
Phase 1Completed
NCT02405520Enterprise Therapeuticslow dosage HPV Vaccine

Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Start: Mar 2015Est. completion: May 2022145 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
Vaccine is the dominant modality (100% of programs)
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.